Engot-Ov44/First Study: A Randomized, Double-Blind, Adaptive, Phase Iii Study Of Platinum-Based Therapy With Dostarlimab (Tsr-042) + Niraparib Versus Standard-Of-Care (Soc) Platinum-Based Therapy As First-Line Treatment Of Stage 3/4 Non-Mucinous Epithelial Ovarian Cancer (Oc).

JOURNAL OF CLINICAL ONCOLOGY(2019)

引用 13|浏览86
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要